
- /
- Supported exchanges
- / US
- / ITRM.NASDAQ
Iterum Therapeutics PLC (ITRM NASDAQ) stock market data APIs
Iterum Therapeutics PLC Financial Data Overview
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Iterum Therapeutics PLC data using free add-ons & libraries
Get Iterum Therapeutics PLC Fundamental Data
Iterum Therapeutics PLC Fundamental data includes:
- Net Revenue:
- EBITDA: -18 412 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-07
- EPS/Forecast: -0.24
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Iterum Therapeutics PLC News

Iterum Therapeutics PLC (ITRM) Q4 2024 Earnings Call Highlights: Navigating Financial ...
Total Operating Expenses (Q4 2024): $3.7 million Total Operating Expenses (Full Year 2024): $18.7 million R&D Costs (Q4 2024): $1.3 million R&D Costs (Full Year 2024): $10.5 million G&A Costs (Q4 2024...


Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
--ORLYNVAHTM Approved by FDA in Q4 2024— --Extended Cash Runway-- --Company to host conference call today at 8:30amET-- DUBLIN and CHICAGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics...

Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025
DUBLIN, Ireland and CHICAGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infe...

Ken Griffin Stock Portfolio: Top 10 Stock Picks
In this piece, we will take a look at the top ten stock picks of Ken Griffin and his hedge fund Citadel Investment Group. If you want to skip our introduction to the billionaire hedge fund boss and hi...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.